EW vs STE stock comparison
Edwards Lifesciences vs. STERIS · data as of November 13, 2026
Edwards Lifesciences (EW) has a market value of about $61.6B, STERIS (STE) about $25.7B. Over their latest twelve months Edwards Lifesciences had revenue of $6.7B and STERIS $6.2B.
On our five checks STERIS scores higher: 3.0 out of 5 (average) against 2.8 (average).
By area, the stronger company is Edwards Lifesciences on future growth; STERIS on track record; STERIS on shareholder returns.
STERIS is cheaper on earnings (P/E 31.4 vs. 60.5).
Edwards Lifesciences leads on 8 of the compared lines and STERIS on 15.
Side by side
| EW | STE | |
|---|---|---|
| Size and price | ||
| Market cap | $61.6B | $25.7B |
| Share price | $107.15 | $264.32 |
| Score | ||
| Overall score (of 5) | 2.8 | 3.0 |
| Value | 0 | 0 |
| Future growth | 4 | 2 |
| Track record | 2 | 3 |
| Financial health | 5 | 5 |
| Shareholder returns | 3 | 5 |
| Valuation | ||
| P/E (TTM) | 60.5 | 31.4 |
| Forward P/E | 33.5 | 21.7 |
| Price / free cash flow | 43.3 | 27.4 |
| Price / sales | 9.2 | 4.2 |
| EV / EBITDA | 35.8 | 16.2 |
| PEG | 8.55 | 2.76 |
| DCF value vs. price | −64% | −43% |
| Business | ||
| Revenue | $6.7B | $6.2B |
| Net income | $1.0B | $827M |
| Free cash flow | $1.4B | $937M |
| Net margin | 15.3% | 13.4% |
| Gross margin (5-yr avg.) | 79.6% | 43.9% |
| ROIC (5-yr avg.) | 16.0% | 6.8% |
| Growth | ||
| Revenue growth (1 yr) | 11.6% | 8.7% |
| Revenue growth (5 yrs, per year) | 6.7% | 13.8% |
| EPS growth (5 yrs, per year) | 7.1% | 11.4% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | $3.9B | -$1.4B |
| Dividend yield | None | 1.04% |
| Shareholder yield | 1.5% | 2.0% |
| Analysts | ||
| Upside to average target | +6% | +6% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: EW TTM to September 30, 2026, STE TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Edwards Lifesciences or STERIS?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) STERIS scores 3.0 out of 5 and Edwards Lifesciences 2.8; the table shows where each one is stronger.
Is Edwards Lifesciences cheaper than STERIS?
On trailing earnings, STERIS trades at a P/E of 31.4 and Edwards Lifesciences at 60.5, so STERIS is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Edwards Lifesciences or STERIS?
Over five years STERIS grew revenue about 13.8% a year and Edwards Lifesciences about 6.7% a year.
Which pays a higher dividend?
Edwards Lifesciences yields nothing (no dividend) and STERIS 1.04%.
Full Edwards Lifesciences analysis → Full STERIS analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.